Acorda Therapeutics (NASDAQ:ACOR) reported Q2 EPS of ($3.15), $2.79 worse than the analyst estimate of ($0.36). Revenue for the quarter came in at $18.2 million versus the consensus estimate of $29.1 million.
Acorda Therapeutics (NASDAQ:ACOR) reported Q2 EPS of ($3.15), $2.79 worse than the analyst estimate of ($0.36). Revenue for the quarter came in at $18.2 million versus the consensus estimate of $29.1 million.